PMID- 35448517
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 2218-1989 (Print)
IS  - 2218-1989 (Electronic)
IS  - 2218-1989 (Linking)
VI  - 12
IP  - 4
DP  - 2022 Apr 6
TI  - Soy Phospholipids Exert a Renoprotective Effect by Inhibiting the Nuclear Factor 
      Kappa B Pathway in Macrophages.
LID - 10.3390/metabo12040330 [doi]
LID - 330
AB  - Complications associated with chronic kidney disease (CKD), which involves kidney 
      inflammation, are a major health problem. Soy protein isolate (SPI) reportedly 
      inhibits CKD exacerbation; however, its detailed action mechanism remains 
      obscure. Therefore, the role of the polar lipid component of SPI in suppressing 
      inflammation was investigated. Zucker fatty rats were divided into three groups 
      and fed a diet containing casein, SPI, or casein + SPI ethanol extract (SPIEE) 
      for 16 weeks. The isoflavones and phospholipids of SPIEE were evaluated for their 
      anti-inflammatory effects. Rats in the SPI and casein + SPIEE groups showed 
      reduced levels of the urinary N-acetyl-beta-d-glucosaminidase and renal IL-1beta mRNA 
      (an inflammatory marker) compared with those in the casein group. In proximal 
      tubular cells, genistein significantly inhibited monocyte chemoattractant 
      protein-1 (MCP-1) expression induced by an IL-1beta stimulus. In macrophages, 
      soybean phospholipids suppressed lipopolysaccharide-induced IL-1beta gene expression 
      by inhibiting the phosphorylation of inhibitor kappaB and p65. Phosphatidylinositol 
      (PI) was found to be essential for inhibition of IL-1beta expression. SPIEE 
      inhibited the exacerbation of kidney disease. Genistein and soybean 
      phospholipids, especially soybean-specific phospholipids containing PI, 
      effectively inhibited the inflammatory spiral in vitro. Hence, daily soybean 
      intake may be effective for inhibiting chronic inflammation and slowing kidney 
      disease progression.
FAU - Ohta, Satoshi
AU  - Ohta S
AD  - Research Institute for Creating the Future, Fuji Oil Holdings Inc., 4-3 
      Kinunodai, Tsukubamirai-shi 300-2497, Ibaraki, Japan.
FAU - Asanoma, Masashi
AU  - Asanoma M
AD  - Soy Ingredients R&D Department, Fuji Oil Co., Ltd., 1 Sumiyoshicho, Izumisano-shi 
      598-8540, Osaka, Japan.
FAU - Irie, Nao
AU  - Irie N
AD  - Research Institute for Creating the Future, Fuji Oil Holdings Inc., 4-3 
      Kinunodai, Tsukubamirai-shi 300-2497, Ibaraki, Japan.
FAU - Tachibana, Nobuhiko
AU  - Tachibana N
AD  - Research Institute for Creating the Future, Fuji Oil Holdings Inc., 4-3 
      Kinunodai, Tsukubamirai-shi 300-2497, Ibaraki, Japan.
FAU - Kohno, Mitsutaka
AU  - Kohno M
AD  - R&D Division Strategy Planning Department, Fuji Oil Co., Ltd., 1 Sumiyoshicho, 
      Izumisano-shi 598-8540, Osaka, Japan.
LA  - eng
PT  - Journal Article
DEP - 20220406
PL  - Switzerland
TA  - Metabolites
JT  - Metabolites
JID - 101578790
PMC - PMC9031346
OTO - NOTNLM
OT  - genistein
OT  - inflammation
OT  - kidney
OT  - macrophage
OT  - phospholipids
OT  - soy
COIS- The authors are employees of Fuji Oil Holdings Inc. or Fuji Oil Co. Ltd. The 
      authors declare no conflict of interest.
EDAT- 2022/04/22 06:00
MHDA- 2022/04/22 06:01
PMCR- 2022/04/06
CRDT- 2022/04/21 20:19
PHST- 2022/03/11 00:00 [received]
PHST- 2022/04/01 00:00 [revised]
PHST- 2022/04/02 00:00 [accepted]
PHST- 2022/04/21 20:19 [entrez]
PHST- 2022/04/22 06:00 [pubmed]
PHST- 2022/04/22 06:01 [medline]
PHST- 2022/04/06 00:00 [pmc-release]
AID - metabo12040330 [pii]
AID - metabolites-12-00330 [pii]
AID - 10.3390/metabo12040330 [doi]
PST - epublish
SO  - Metabolites. 2022 Apr 6;12(4):330. doi: 10.3390/metabo12040330.